Cargando…

Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression

BACKGROUND: Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized. In the present study, we aimed to show the efficacy of multidisciplinary therapy for patients who had failed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondo, Masaaki, Numata, Kazushi, Hara, Koji, Nozaki, Akito, Fukuda, Hiroyuki, Chuma, Makoto, Maeda, Shin, Tanaka, Katsuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498900/ https://www.ncbi.nlm.nih.gov/pubmed/28717362 http://dx.doi.org/10.1155/2017/5728946

Ejemplares similares

Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment
por: Fukuda, Hiroyuki, et al.
Publicado: (2018)

Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study
por: Nozaki, Akito, et al.
Publicado: (2021)

Usefulness of 3D slicer for the planning and monitoring of hepatocellular carcinoma treatment using FUS
por: Doba, Nobutaka, et al.
Publicado: (2015)

Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child–Pugh classification B: A retrospective observational study
por: Komiyama, Satoshi, et al.
Publicado: (2020)

Respiratory motion tracking system of hepatocellular carcinoma treatment using FUS
por: Fukuda, Hiroyuki, et al.
Publicado: (2015)

Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4–B1: a pilot study
por: Wang, Feiqian, et al.
Publicado: (2021)

Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases
por: Tarao, Kazuo, et al.
Publicado: (2020)

High-intensity focused ultrasound ablation assisted using color Doppler imaging for the treatment of hepatocellular carcinomas
por: Fukuda, Hiroyuki, et al.
Publicado: (2013)

Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma
por: Wang, Feiqian, et al.
Publicado: (2021)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma
por: Tarao, Kazuo, et al.
Publicado: (2021)

Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh Class A Liver function: A Pilot Study
por: Wang, Feiqian, et al.
Publicado: (2022)

Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment
por: Sawada, Koji, et al.
Publicado: (2019)

Diagnostic Value of Imaging Methods in the Histological Four Grading of Hepatocellular Carcinoma
por: Wang, Feiqian, et al.
Publicado: (2020)

Added Value of Ultrasound-Based Multimodal Imaging to Diagnose Hepatic Sclerosed Hemangioma before Biopsy and Resection
por: Wang, Feiqian, et al.
Publicado: (2022)

Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
por: Komiyama, Satoshi, et al.
Publicado: (2020)

Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
por: Kondo, Masaaki, et al.
Publicado: (2019)

Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
por: Morinaga, Ryota, et al.
Publicado: (2018)

Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma
por: Takada, Juichi, et al.
Publicado: (2015)

Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report
por: Komiyama, Satoshi, et al.
Publicado: (2021)

Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis
por: Tarao, Kazuo, et al.
Publicado: (2021)

Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2020)

Author Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2021)

Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma
por: Hao, Yoshiteru, et al.
Publicado: (2017)

Abdominal Ultrasound and Treatment of Hepatocellular Carcinoma
por: Numata, Kazushi
Publicado: (2021)

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
por: Ascierto, Paolo A., et al.
Publicado: (2020)

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
por: Zeyen, Thomas, et al.
Publicado: (2023)

Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
por: Zeyen, Thomas, et al.
Publicado: (2023)

Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma
por: Funaoka, Akihiro, et al.
Publicado: (2021)

Safety and Efﬁcacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis
por: Ogushi, Katsuaki, et al.
Publicado: (2020)

Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment
por: Ochi, Masanori, et al.
Publicado: (2021)

The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
por: Kawamura, Atsushi, et al.
Publicado: (2022)

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
por: Chuma, Makoto, et al.
Publicado: (2020)

Differential diagnosis of solid pancreatic lesions using contrast-enhanced three-dimensional ultrasonography
por: Miwa, Haruo, et al.
Publicado: (2014)

Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells
por: Chen, Su-Hong, et al.
Publicado: (2022)

Diverse definitions of prolonged labour and its consequences with sometimes subsequent inappropriate treatment
por: Nystedt, Astrid, et al.
Publicado: (2014)

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_r7ahb2utkj3qd03llq5roh293k